This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta.
.
Human | |
---|---|
Gene Name: | PDE6B |
Uniprot: | P35913 |
Entrez: | 5158 |
Belongs to: |
---|
cyclic nucleotide phosphodiesterase family |
CSNB3; EC 3.1.4; EC 3.1.4.35; GMP-PDE beta; PDEBrod cGMP-phosphodiesterase beta-subunit; phosphodiesterase 6B, cGMP-specific, rod, beta; rd1; rod cGMP-specific 3'-5'-cyclic phosphodiesterase subunit beta; RP40CSNBAD2
Mass (kDA):
98.336 kDA
Human | |
---|---|
Location: | 4p16.3 |
Sequence: | 4; NC_000004.12 (587325..670892) |
Membrane; Lipid-anchor.
If you're looking for a PDE6B marker, you've come to the right place. This article will provide you with information about Steven Boster, his Anti-CD8 alpha/Cd8a Antibody Picoband(tm), and the PDE6B Marker. You may be wondering how it works. It's a simple protein that's found on many different types of cells. If you're a scientist and want to know more, read on!
One of Dr. Steven Boster's favorite uses of the PDE6B marker is in the treatment of equine cancer. This marker was developed to determine the risk of COVID-19 recurrence. Boster developed the test in 1996 and was the first veterinarian to use it in equine cancer. The PDE6B marker is a powerful tool in the diagnosis of COVID-19, a cancer that mainly affects the nervous system. It is a good test to confirm the presence of this disease in the animal.
Anti-CD8 alpha/Cd8, also known as IL-8, is a soluble monoclonal antibody that reacts with mouse CD8a molecule. CD8a is a cell surface receptor that is expressed in two forms, as a homodimer or heterodimer. CD8 alpha and beta are expressed by a majority of thymocytes, dendritic cells and gamma delta T cells.
OKT8 and Cd8a antibodies have distinct properties. Anti-CD8a antibodies inhibit the staining of pMHCI tetramer and enhance pMHCI tetramer binding. OKT8 and CD8a antibodies are both potent activators, with different effects depending on the specific antibody clone.
The differences between anti-CD8 antibodies are largely due to the heterogeneity of these antibodies. However, these antibodies are capable of activating T-cell effectors. This heterogeneity is important to understand when interpreting results. In addition to activating T cells, antibody-mediated CD8 engagement is important in signalling.
The anti-CD8 alpha/Cd8A antibody 53-6.7 is a functional assay that has been tested on mouse thymocytes and splenocytes. Its optimal performance in the assay can be achieved by carefully titrating the amount of antibody per sample. It has undergone SDS-PAGE and HPLC purification.
OKT8 antibody increased staining intensity and tetramer binding by inhibiting pMHCII-mediated interactions. The OKT8 antibody also enhanced the staining intensity of ELAGIGILTV-derived epitope in HLA A*0201-restricted T cells. This effect was also seen in CD8-null T-cells.
The PDE6B gene encodes a protein that inhibits the cGMP phosphodiesterase enzyme. The enzyme is activated by the photoreceptor G protein transducin. This protein also contains the inhibitory Pgamma subunit. The chimeric PDE6alpha gene contains the catalytic domain of PDE5 and shares the same binding site with PDE6alpha.
To test the expression of PDE6B, a microplate reader capable of reading absorbance at 450 nm is required. Boster pipettes can dispense 0.5-ml volumes of aqueous solutions. For large volumes of samples, multichannel pipettes are recommended. Lastly, Boster Bio offers product credits for sharing the results of your experiments. If you plan to publish your research, consider using the PDE6B marker.
PMID: 1720239 by Weber B., et al. Genomic organization and complete sequence of the human gene encoding the beta-subunit of the cGMP phosphodiesterase and its localisation to 4p16.3.
PMID: 1338685 by Khramtsov N.V., et al. Structural studies of cDNA and the gene for the beta-subunit of cGMP phosphodiesterase from human retina.